Cardiovascular Today—March 12, 2026

This week’s Cardiovascular update highlights new clinical guidance, device innovation, real-world heart-failure data, biomarker insights, and AI-enabled preventive screening initiatives.

In Today’s Newsletter

Dive deeper

🫀 Mitria Medical starts US compassionate-use experience with Subvalvular Spacer [1] [US • 06 Mar 2026]

https://cardiovascularnews.com/mitria-medicals-subvalvular-spacer-implanted-under-compassionate-use/
Context: Mitria Medical’s Subvalvular Spacer (SVS) was implanted at Cleveland Clinic under the US FDA single-patient expanded access programme for severe functional mitral regurgitation.
Key point: The company said this was the first US compassionate-use implant, and the device performed as intended in a patient considered unsuitable for existing percutaneous options.
Implication: May influence prescriber choice and payer reviews pending full data.

📘 ACC/AHA publishes first multisociety US adult acute PE guideline [2] [US • 06 Mar 2026]

https://cardiovascularnews.com/first-acc-aha-acute-pe-guidelines-provide-roadmap-for-management/
Context: The ACC/AHA Joint Committee, with eight collaborating societies, published new adult acute pulmonary embolism guidance in JACC and Circulation.
Key point: The guideline introduces a five-category severity framework, recommends care pathways by setting, and gives strong support to pulmonary embolism response teams (PERTs).
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

❤️ CVRx Barostim registry shows LVEF and NYHA improvement in HFrEF [3] [US • 06 Mar 2026]

https://cardiovascularnews.com/tht-2026-hfref-patients-undergoing-baroreflex-activation-therapy-see-shift-in-lvef/
Context: Six-month REBALANCE registry data on Barostim (CVRx) were presented at THT 2026; the postmarket observational study involves 435 patients.
Key point: Investigators reported improved LVEF and NYHA class at six months, while NT-proBNP, BNP and eGFR were largely unchanged.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🩺 CathWorks FFRangio gains US traction, outcomes track with pressure-wire guidance [4] [US • 09 Mar 2026]

https://cardiovascularnews.com/crt-2026-late-breaking-data-highlight-growing-adoption-of-angiography-derived-fractional-flow-reserve/
Context: Late-breaking CRT 2026 and simultaneously published Medicare data compared angiography-derived physiology with invasive pressure-wire assessment in PCI and non-PCI cohorts.
Key point: ADP use grew nearly eightfold between 2019 and 2024, and matched analyses showed similar 2-year MACE rates versus invasive pressure-wire guidance.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧪 NT-proBNP trajectory stratifies long-term risk after T-TEER [5] [EU • 04 Mar 2026]

https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/heart-failure-biomarker-identifies-long-term-risk-t-teer-patients
Context: A JACC: Cardiovascular Interventions analysis evaluated more than 2,200 T-TEER patients treated across 30 European centres from 2016 to 2024.
Key point: Higher baseline NT-proBNP and rising early post-procedural levels were associated with greater risk of all-cause mortality or first heart-failure hospitalization during follow-up.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🤖 Singapore’s ACE-AI will intensify preventive cardiovascular screening [6] [Singapore • 05 Mar 2026]

https://www.channelnewsasia.com/singapore/ai-diabetes-high-cholesterol-health-screening-woodlands-5972401
Context: Singapore’s Ministry of Health plans to deploy ACE-AI, developed by Synapxe, within Healthier SG from early next year.
Key point: Patients flagged as high risk for diabetes or hyperlipidaemia will move from once-every-three-years to annual cardiovascular disease risk screening, with subsidies maintained.
Implication: May expand screening, initiation, and follow-up at scale.

🚑 Pre-MIRACLE2 brings neurological risk stratification into the ambulance [7] [UK • 09 Mar 2026]

https://www.kcl.ac.uk/news/algorithm-allows-paramedics-to-predict-brain-damage-risk-after-cardiac-arrest
Context: King’s College London investigators reported RAPID-MIRACLE findings at CRT 2026, validating pre-hospital use of the MIRACLE2 score after out-of-hospital cardiac arrest.
Key point: A simplified version without a blood test, Pre-MIRACLE2, retained near-equivalent accuracy and may help paramedics identify patients who could benefit from direct transfer to specialist centres.
Implication: May expand screening, initiation, and follow-up at scale.

💧 Relief Cardiovascular reports positive 90-day first-in-human heart-failure device data [8] [EU • 09 Mar 2026]

https://citoday.com/news/relief-cardiovasculars-relief-fih-meets-all-3-month-endpoints?c4src=center
Context: The prospective multicentre RELIEF-FIH study enrolled eight patients at three European sites, evaluating the Relief system in heart-failure congestion.
Key point: The company said all 90-day endpoints were met, including procedural safety, sustained on-demand renal-vein flow, and accurate automatic hemodynamic pressure measurement.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Rice and Baylor report CRISPR-based mitochondrial tuning for heart failure models [9] [US • 09 Mar 2026]

https://www.news-medical.net/news/20260309/New-CRISPR-technique-boosts-mitochondrial-function-to-treat-heart-failure.aspx
Context: Researchers from Rice University and Baylor College of Medicine described a nonediting CRISPR approach in Molecular Therapy to increase mitochondrial function.
Key point: The method improved mitochondrial performance in human cell types, cardiomyocytes, animal models, and donor heart tissue, according to the research summary.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Structural heart innovation remains active across both mitral and tricuspid disease, with new devices and biomarker-based follow-up shaping patient selection [1][5].
Heart-failure management is broadening beyond drugs, from Barostim neuromodulation to implantable venous-pressure systems and upstream mitochondrial targeting [3][8][9].
Evidence generation is shifting toward real-world and operational datasets, including Medicare analyses, postmarket registries, and ambulance-based validation studies [3][4][7].
Health systems are pairing clinical risk tools with workflow changes, seen in PERT guideline support and Singapore’s AI-enabled preventive screening model [2][6].
Several items are still early-stage, observational, company-reported, or press-release-led, so adoption will depend on fuller datasets and external validation [3][4][8][9].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Cardiovascular archive on our research hub page

FAQ

What is Mitria Medical’s Subvalvular Spacer designed to do?

It is a transcatheter device intended to address posterior leaflet tethering in functional mitral regurgitation while preserving anterior leaflet motion. The reported US case was performed under compassionate use at Cleveland Clinic [1].

What changed in the new ACC/AHA acute PE guideline?

The document adds a new severity-based classification, specifies care by setting, and strongly endorses multidisciplinary PERT models. It is presented as the first US multisociety adult acute PE guideline of this kind [2].

What did REBALANCE show for Barostim in HFrEF?

The registry showed improvement in LVEF and NYHA class at six months, with no major shift in NT-proBNP or eGFR. It is a real-world observational dataset, not a new randomized efficacy readout [3].

Why does NT-proBNP matter after T-TEER?

In the European analysis, both baseline NT-proBNP and early post-procedural increases were associated with worse long-term outcomes after tricuspid transcatheter edge-to-edge repair. The study suggests a simple biomarker may improve follow-up risk stratification [5].

How will Singapore’s ACE-AI affect screening?

ACE-AI is intended to identify people at high risk of diabetes or hyperlipidaemia and move them to annual cardiovascular disease risk screening under Healthier SG. Doctors are strongly encouraged, but not required, to use it [6].

What is Pre-MIRACLE2 and why is it useful?

It is a pre-hospital adaptation of the MIRACLE2 neurological risk score for patients with return of spontaneous circulation after out-of-hospital cardiac arrest. The validated no-blood-test version could help paramedics decide on earlier transfer to specialist centres [7].

Entities / Keywords

Mitria Medical, Subvalvular Spacer, SVS, functional mitral regurgitation, Cleveland Clinic
ACC, AHA, acute pulmonary embolism, PE, PERT, JACC, Circulation
CVRx, Barostim, baroreflex activation therapy, BAT, REBALANCE, HFrEF
CathWorks, FFRangio, angiography-derived physiology, ADP, fractional flow reserve, PCI
NT-proBNP, T-TEER, tricuspid transcatheter edge-to-edge repair, tricuspid regurgitation
Singapore Ministry of Health, MOH, Synapxe, ACE-AI, Healthier SG, hyperlipidaemia
King’s College London, MIRACLE2, Pre-MIRACLE2, RAPID-MIRACLE, OHCA, ROSC
Relief Cardiovascular, RELIEF-FIH, Relief system, heart-failure congestion
Rice University, Baylor College of Medicine, CRISPR, mitochondrial function, Molecular Therapy